JP2022548689A5 - - Google Patents
Info
- Publication number
- JP2022548689A5 JP2022548689A5 JP2022517372A JP2022517372A JP2022548689A5 JP 2022548689 A5 JP2022548689 A5 JP 2022548689A5 JP 2022517372 A JP2022517372 A JP 2022517372A JP 2022517372 A JP2022517372 A JP 2022517372A JP 2022548689 A5 JP2022548689 A5 JP 2022548689A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal according
- degrees
- powder
- ray diffraction
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902322P | 2019-09-18 | 2019-09-18 | |
| US62/902,322 | 2019-09-18 | ||
| PCT/US2020/051563 WO2021055797A1 (en) | 2019-09-18 | 2020-09-18 | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548689A JP2022548689A (ja) | 2022-11-21 |
| JP2022548689A5 true JP2022548689A5 (enExample) | 2023-09-25 |
| JP7706166B2 JP7706166B2 (ja) | 2025-07-11 |
Family
ID=72717922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517372A Active JP7706166B2 (ja) | 2019-09-18 | 2020-09-18 | タンパク質アルギニンメチルトランスフェラーゼ５（ｐｒｍｔ５）の選択的阻害剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12414953B2 (enExample) |
| EP (1) | EP4031555A1 (enExample) |
| JP (1) | JP7706166B2 (enExample) |
| KR (1) | KR20220065811A (enExample) |
| CN (1) | CN114829370B (enExample) |
| AU (1) | AU2020349553A1 (enExample) |
| BR (1) | BR112022004630A2 (enExample) |
| CA (1) | CA3154566A1 (enExample) |
| IL (1) | IL291417B2 (enExample) |
| MX (1) | MX2022003340A (enExample) |
| WO (1) | WO2021055797A1 (enExample) |
| ZA (1) | ZA202203680B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116211869B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 含dna损伤修复抑制剂的药物混合物及混合方法、用途 |
| WO2024170488A1 (en) | 2023-02-13 | 2024-08-22 | Astrazeneca Ab | Prmt5 inhibitor for use in cancer therapy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3657744A (en) | 1970-05-08 | 1972-04-25 | Univ Minnesota | Method for fixing prosthetic implants in a living body |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5040548A (en) | 1989-06-01 | 1991-08-20 | Yock Paul G | Angioplasty mehtod |
| US5350395A (en) | 1986-04-15 | 1994-09-27 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US5061273A (en) | 1989-06-01 | 1991-10-29 | Yock Paul G | Angioplasty apparatus facilitating rapid exchanges |
| US4748982A (en) | 1987-01-06 | 1988-06-07 | Advanced Cardiovascular Systems, Inc. | Reinforced balloon dilatation catheter with slitted exchange sleeve and method |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| CA1322628C (en) | 1988-10-04 | 1993-10-05 | Richard A. Schatz | Expandable intraluminal graft |
| US5292331A (en) | 1989-08-24 | 1994-03-08 | Applied Vascular Engineering, Inc. | Endovascular support device |
| US5674278A (en) | 1989-08-24 | 1997-10-07 | Arterial Vascular Engineering, Inc. | Endovascular support device |
| US6344053B1 (en) | 1993-12-22 | 2002-02-05 | Medtronic Ave, Inc. | Endovascular support device and method |
| AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US20170198006A1 (en) * | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016022605A1 (en) * | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| MX2017010844A (es) | 2015-02-24 | 2017-12-07 | Pfizer | Derivados de nucleosidos sustituidos utiles como agentes anticancerosos. |
| MA41827A (fr) * | 2015-03-27 | 2018-01-30 | Pharmacyclics Llc | Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton |
| AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| AU2017230658B2 (en) | 2016-03-10 | 2021-03-04 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as PRMT5 inhibitors |
| CN108430987B (zh) * | 2016-06-02 | 2021-06-18 | 上海海雁医药科技有限公司 | Pi3k抑制剂及其药学上可接受的盐和多晶型物及其应用 |
| WO2017218802A1 (en) * | 2016-06-15 | 2017-12-21 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| TN2019000087A1 (en) * | 2016-10-03 | 2020-07-15 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
| KR101785870B1 (ko) | 2016-11-03 | 2017-10-13 | 한규락 | 오르골 장치 |
| EP3939986A1 (en) | 2017-08-09 | 2022-01-19 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2019084470A1 (en) | 2017-10-26 | 2019-05-02 | Prelude Therapeutics, Incorporated | SELECTIVE INHIBITORS OF THE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) |
| AU2019235912B2 (en) | 2018-03-14 | 2024-03-21 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) |
-
2020
- 2020-09-18 WO PCT/US2020/051563 patent/WO2021055797A1/en not_active Ceased
- 2020-09-18 EP EP20785886.1A patent/EP4031555A1/en active Pending
- 2020-09-18 CA CA3154566A patent/CA3154566A1/en active Pending
- 2020-09-18 AU AU2020349553A patent/AU2020349553A1/en active Pending
- 2020-09-18 JP JP2022517372A patent/JP7706166B2/ja active Active
- 2020-09-18 KR KR1020227012615A patent/KR20220065811A/ko active Pending
- 2020-09-18 CN CN202080074610.XA patent/CN114829370B/zh active Active
- 2020-09-18 IL IL291417A patent/IL291417B2/en unknown
- 2020-09-18 MX MX2022003340A patent/MX2022003340A/es unknown
- 2020-09-18 US US17/761,717 patent/US12414953B2/en active Active
- 2020-09-18 BR BR112022004630A patent/BR112022004630A2/pt unknown
-
2022
- 2022-03-30 ZA ZA2022/03680A patent/ZA202203680B/en unknown
-
2025
- 2025-08-18 US US19/302,476 patent/US20250367205A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017061547A5 (enExample) | ||
| JP7546548B2 (ja) | 組み合わせ療法 | |
| JP2022548689A5 (enExample) | ||
| JP2022520382A5 (enExample) | ||
| JP2022509724A (ja) | 組み合わせ療法 | |
| KR20230159363A (ko) | Cdk 억제제의 공결정 | |
| JP2022500385A (ja) | 組み合わせ療法 | |
| TW200924786A (en) | Certain compounds, compositions and methods | |
| JP2014502641A5 (enExample) | ||
| WO2018210296A1 (zh) | 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2021524835A5 (enExample) | ||
| TW202313050A (zh) | 組合療法 | |
| JP2024520630A5 (enExample) | ||
| IL291417B1 (en) | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) | |
| US20250152569A1 (en) | Treatment of cell proliferation-associated conditions using a combination of a clb-b inhibitor and an additional therapeutic agent | |
| JP2022535850A5 (enExample) | ||
| CN116323590A (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| CN114652723A (zh) | 治疗非小细胞肺癌的喹啉衍生物 | |
| TW201904577A (zh) | N-(2-(2-二甲胺基)乙氧基)-4-甲氧基-5-((4-(1-甲基-1h-吲哚-3-基)嘧啶-2-基)胺基)苯基)丙烯醯胺及其鹽之醫藥調配物 | |
| JP2024534517A5 (enExample) | ||
| JP2020514344A5 (enExample) | ||
| JP2020536048A5 (enExample) | ||
| JP2013537901A5 (enExample) | ||
| JP2023530786A5 (enExample) | ||
| WO2024015864A1 (en) | Cbl-b inhibitors and anti-pd1/anti-pd-l1 for use in the treatment of cancer |